SCHEMBL24258072

SCHEMBL24258072

O=c1ccc(-c2noc(Cc3ccc(Cl)cc3)n2)c[nH]1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 3/20 0.58
TSHR P16473 3/20 0.58
SMN1; SMN2 Q16637 2/20 0.58
ALOX15 P16050 1/20 0.58
KMT2A Q03164 3/20 0.56
LMNA P02545 2/20 0.56
MEN1 O00255 2/20 0.56
L3MBTL1 Q9Y468 2/20 0.56
CYP1A2 P05177 2/20 0.55
CYP3A4 P08684 1/20 0.55
GAA P10253 1/20 0.55
CYP2D6 P10635 1/20 0.55
CYP2C9 P11712 1/20 0.55
CYP2C19 P33261 1/20 0.55
ERCC1 P07992 1/20 0.55
ERCC4 Q92889 1/20 0.55
TDP1 Q9NUW8 2/20 0.54
RAB9A P51151 1/20 0.54
NOTUM Q6P988 2/20 0.49
ALDH1A1 P00352 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24258048 0.87 TDP1 (0.57) MAPK1TSHRSMN1; SMN2ALOX15KMT2A
SCHEMBL24258084 0.87 S1PR1 (0.58) MAPK1TSHRSMN1; SMN2KMT2AMEN1
SCHEMBL24258053 0.86 ERCC1 (0.49) MAPK1TSHRSMN1; SMN2ALOX15KMT2A
SCHEMBL24258021 0.85 ERCC1 (0.48) MAPK1TSHRSMN1; SMN2ALOX15KMT2A
SCHEMBL24258039 0.82 ERCC1 (0.45) MAPK1TSHRSMN1; SMN2ALOX15KMT2A
SCHEMBL26005131 0.81 ERCC1 (0.43) MAPK1TSHRSMN1; SMN2ALOX15KMT2A
SCHEMBL24258023 0.81 S1PR1 (0.43) MAPK1TSHRSMN1; SMN2ALOX15KMT2A
SCHEMBL26004727 0.80 MAPT (0.47) MAPK1TSHRSMN1; SMN2ALOX15KMT2A
SCHEMBL24258083 0.78 ERCC1 (0.43) MAPK1TSHRSMN1; SMN2ALOX15KMT2A
SCHEMBL24258036 0.76 DAO (0.41) MAPK1SMN1; SMN2KMT2ALMNAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230265082-A1 SUBSTITUTED 1,2,4-OXADIAZOLES AS SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 DANA-FARBER CANCER INSTITUTE, INC. 2023-08-24 US disclosed
US-20230265082-A1 SUBSTITUTED 1,2,4-OXADIAZOLES AS SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 DANA-FARBER CANCER INSTITUTE, INC. 2023-08-24 US disclosed
WO-2022035805-A1 SUBSTITUTED 1,2,4-OXADIAZOLES AS SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 DANA-FARBER CANCER INSTITUTE, INC. (US) 2022-02-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230265082-A1 SUBSTITUTED 1,2,4-OXADIAZOLES AS SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 USP28, USP1, USP18 MAPK1 829/4885TSHR 4539/4885SMN1; SMN2 796/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.